Tamoxifen is the endocrine treatment of choice for hormone-responsive early and advanced breast cancer. Newly developed biodegradable luteinizing hormone-releasing hormone super agonists represent a practical and effective treatment for metastatic disease in premenopausal women. Progestins or aromatase inhibitors are useful therapies in patients who relapse from antiestrogens. Currently, there is no indication that improved survival can be achieved by combined endocrine therapy or combined chemo-hormonal therapy.
|Original language||English (US)|
|Number of pages||20|
|Journal||Endocrinology and Metabolism Clinics of North America|
|Publication status||Published - 1991|
All Science Journal Classification (ASJC) codes